Catheter ablation for monomorphic ventricular tachycardia in Brugada syndrome patients: detailed characteristics and long-term follow-up
Brugada syndrome (BrS) is a risk of sudden cardiac death due to polymorphic ventricular tachycardia and ventricular fibrillation with unusual monomorphic ventricular tachycardia (MVT). Detailed characteristics of MVT and long-term outcome of catheter ablation are still unknown. This study is aimed to identify the detailed characteristics and long-term follow-up of catheter ablation in BrS patients.
We evaluated 188 patients who were diagnosed with BrS from March 1999 to March 2018. Of those, patients who developed MVT and underwent catheter ablation were included. We identified eight MVTs in seven BrS patients.
Three of them already had implantable cardioverter-defibrillator, and MVTs were terminated by cardioversion or anti-tachycardia pacing. Four patients presented with MVT originating from the right ventricular outflow tract, one patient had MVT arising from the LV septum, one patient had MVT arising from the tricuspid annulus, and one patient had bundle branch reentry ventricular tachycardia. All MVTs were successfully treated by catheter ablation in the acute phase, and seven of eight (87.5%) were free from ventricular tachyarrhythmia during the long-term follow-up (median, 7.2 years).
All MVT cases were successfully treated by catheter ablation. We observed high ventricular arrhythmia free rate following catheter ablation during the long-term follow-up period. BrS patients who developed MVT should consider catheter ablation.
KeywordsAnti-tachycardia pacing Brugada syndrome Catheter ablation Implantable cardioverter-defibrillator Monomorphic ventricular tachycardia
Compliance with ethical standards
This retrospective observational study was approved by the Institutional Review Board of Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Ueyama T, Shimizu A, Esato M, Yoshiga S, Sawa A, Suzuki S, et al. Pilsicainide-induced Brugada-type ECG and ventricular arrhythmias originating from the left posterior fascicle in a case with Brugada syndrome associated with idiopathic left ventricular tachycardia. Europace. 2008;10:86–90.CrossRefGoogle Scholar
- 8.Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932–63.CrossRefGoogle Scholar
- 10.Kitamura T, Fukamizu S, Kawamura I, Hojo R, Aoyama Y, Komiyama K, et al. Long-term efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with Brugada syndrome and an implantable cardioverter-defibrillator to prevent inappropriate shock therapy. Heart Rhythm. 2016;13:1455–9.CrossRefGoogle Scholar
- 18.Nakashima T, Takasugi N, Sahashi Y, Suzuki K, Kubota T, Aoyama T, et al. Ventricular tachycardia sensitive to antitachycardia pacing in a patient with severely symptomatic Brugada syndrome. J Interv Card Electrophysiol. 2018;55:239. https://doi.org/10.1007/s10840-018-0464-6.CrossRefPubMedGoogle Scholar